Melanoma Relatlimab Nivolumab

Overview

About this study

The purpose of this study is to determine whether Nivolumab in combination with Relatlimab is more effective than Nivolumab by itself in treating unresectable Melanoma or Melanoma that has spread

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Participants must have histologically confirmed Stage III (unresectable) or Stage IV
melanoma, per the AJCC staging system

- Participants must not have had prior systemic anticancer therapy for unresectable or
metastatic melanoma

- Tumor tissue from an unresectable or metastatic site of disease must be provided for
biomarker analyses

Exclusion Criteria:

- Participants must not have active brain metastases or leptomeningeal metastases

- Participants must not have uveal melanoma

- Participants must not have an active, known, or suspected autoimmune disease

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/8/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Svetomir Markovic, M.D., Ph.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Roxana Dronca, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions